These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26726023)

  • 41. Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts.
    van Straten G; van Dalen D; Mesu SJ; Rothuizen J; Teske E; Spee B; Favier RP; van Geijlswijk IM
    J Vet Intern Med; 2019 May; 33(3):1331-1335. PubMed ID: 30916412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hepatic encephalopathy. L-ornithine-L-aspartate stimulate detoxification capacity of the liver].
    Ameri AA
    MMW Fortschr Med; 2010 Jun; 152(22):42-3. PubMed ID: 20590033
    [No Abstract]   [Full Text] [Related]  

  • 43. Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE.
    Kircheis G
    Metab Brain Dis; 2016 Dec; 31(6):1365-1367. PubMed ID: 27838865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperammonemic encephalopathy associated with portal vein thrombosis in a thoroughbred foal.
    Ness SL; Kennedy LA; Slovis NM
    J Vet Intern Med; 2013; 27(2):382-6. PubMed ID: 23363403
    [No Abstract]   [Full Text] [Related]  

  • 45. Establishment of hyperammonemia mode in yellow catfish and the mitigation of exogenous L-ornithine-L-aspartate.
    Zhang M; Fan Y; Jiang H; Shao J; Li M
    Dev Comp Immunol; 2022 Oct; 135():104487. PubMed ID: 35803415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia.
    Jamshidzadeh A; Heidari R; Abasvali M; Zarei M; Ommati MM; Abdoli N; Khodaei F; Yeganeh Y; Jafari F; Zarei A; Latifpour Z; Mardani E; Azarpira N; Asadi B; Najibi A
    Biomed Pharmacother; 2017 Feb; 86():514-520. PubMed ID: 28024286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Cirrhotic liver gives up in breaking up of ammonia. Poison for the brain].
    MMW Fortschr Med; 2004 Jan; 146(5):51. PubMed ID: 15035428
    [No Abstract]   [Full Text] [Related]  

  • 49. Ammonia-lowering strategies for the treatment of hepatic encephalopathy.
    Rose CF
    Clin Pharmacol Ther; 2012 Sep; 92(3):321-31. PubMed ID: 22871998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure.
    Pérez Hernández JL; Higuera de la Tijera F; Serralde-Zúñiga AE; Abdo Francis JM
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S66-9. PubMed ID: 22228885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Piscine insights into comparisons of anoxia tolerance, ammonia toxicity, stroke and hepatic encephalopathy.
    Walsh PJ; Veauvy CM; McDonald MD; Pamenter ME; Buck LT; Wilkie MP
    Comp Biochem Physiol A Mol Integr Physiol; 2007 Jun; 147(2):332-43. PubMed ID: 17046301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arterial and venous ammonia concentrations in the diagnosis of canine hepato-encephalopathy.
    Rothuizen J; van den Ingh TS
    Res Vet Sci; 1982 Jul; 33(1):17-21. PubMed ID: 7134643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
    Kristiansen RG; Rose CF; Ytrebø LM
    Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New strategies for treating hepatic encephalopathy.
    Gómez-Gutiérrez C; Manzano-Robleda MC; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2014; 13(3):409-11. PubMed ID: 24756021
    [No Abstract]   [Full Text] [Related]  

  • 55. Hepatic encephalopathy: clinical signs, pathogenesis, and treatment.
    Taboada J; Dimski DS
    Vet Clin North Am Small Anim Pract; 1995 Mar; 25(2):337-55. PubMed ID: 7785167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic Encephalopathy.
    Gow AG
    Vet Clin North Am Small Anim Pract; 2017 May; 47(3):585-599. PubMed ID: 28069286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The treatment of hepatic encephalopathy with Hepa-Mertz].
    Podymova SD; Bueverov AO; Nadinskaia MIu
    Ter Arkh; 1995; 67(6):45-7. PubMed ID: 7667779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imaging diagnosis-transcranial color-coded duplex sonography in a dog with hepatic encephalopathy.
    Duque J; Dominguez-Roldan JM; Casamian-Sorrosal D; Barrera-Chacon R
    Vet Radiol Ultrasound; 2011; 52(1):111-3. PubMed ID: 21322397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.
    Butterworth RF
    Drugs R D; 2021 Jun; 21(2):123-132. PubMed ID: 33890246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
    Romero Gómez M; Bautista JD; Grande L; Ramos Guerrero RM; Sánchez Muñoz D
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():40-8. PubMed ID: 15195533
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.